REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (UL1TR002319)
  • National Institutes of Health (UM1AI109568)
  • National Institutes of Health (OT2HL161847)
  • National Institutes of Health (OT2OD032581)
  • National Institutes of Health (U01DK100846)
  • National Institutes of Health (U54DK083912)
  • National Institutes of Health (U2CDK114886)
  • National Institutes of Health (R01MD014712)
  • Novo Nordisk
  • Doris Duke Charitable Foundation
  • Juvenile Diabetes Research Foundation Canada (3-SRA-2022-1243-M-B)
  • Juvenile Diabetes Research Foundation Canada (3-SRA-2023-1373-M-B)
  • Bayer

This publication has 26 references indexed in Scilit: